Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Aqualane Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,752,515

250 payments

Through program year 2025, Aqualane Clinical Research is reported as receiving $1,752,515 in research payments, across 250 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $918,226 103
2024 Research $260,326 61
2023 Research $468,698 80
2022 Research $105,265 6

Breakdown

Who paid Research payments · program years 2022–2025
  1. Janssen Research & Development, LLC $616,161 30 payments
  2. E.R. Squibb & Sons, L.L.C. $398,445 7 payments
  3. Alnylam Pharmaceuticals Inc. $248,850 114 payments
  4. Novartis Pharmaceuticals Corporation $178,393 3 payments
  5. Moderna TX, Inc. $126,607 39 payments
  6. Genentech, Inc. $84,833 17 payments
  7. Regeneron Pharmaceuticals, Inc. $49,188 27 payments
  8. TG Therapeutics, Inc. $37,740 9 payments
  9. Genzyme Corporation $12,212 3 payments
  10. Ares Trading SA $85 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $616,161 30 payments
  2. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $378,126 2 payments
  3. A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) $220,852 56 payments
  4. A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light $176,859 1 payment
  5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $116,180 35 payments
  6. Phase II Study for Moderate Ad $84,833 17 payments
  7. Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis $49,188 27 payments
  8. Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) $27,998 58 payments
  9. (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study $23,740 5 payments
  10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) $16,200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record